FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979527793> ?p ?o ?g. }

• W2979527793 endingPage "689" @default.
• W2979527793 startingPage "689" @default.
• W2979527793 abstract "Abstract Background: The aim of FVIII prophylaxis in Hemophilia A management is the reduction of risk for any bleed events (BE) in order to preserve long-term joint health and QOL. One proposed measure of the ideal prophylactic outcome is the virtual elimination of all BE not associated with trauma and/or of spontaneous etiology. Given the wide inter-patient variance in PK parameters, long-term prophylaxis outcomes and costs of therapy, PK-guided dosing has become an attractive approach to add more precision to dosing decisions and improve outcomes. Knowledge of the appropriate FVIII trough target for each individual patient to achieve a bleed-free outcome is needed however to design the ideal personalized PK-guided regimen. Objective: Model individual FVIII trough targets for achieving ideal outcomes in hemophilia A patients prescribed PK-guided prophylaxis every third day. Methods: FVIII infusion and BE records, and PK parameters from each subject participating in the 12-month PK-guided dosing arm of the randomized rAHF-PFM prophylaxis study (Valentino et al, 2012) were used to determine the predicted FVIII level at time of each BE. Median and maximum predicted FVIII values at time of spontaneous/non-trauma BE for all sites, and for joint and non-joint sites were estimated per subject. Number (%) of subjects with any spontaneous/non-trauma BE that occurred at predicted FVIII levels (maximum value and/or median value for those with more than one bleed) above and below specific theoretical FVIII trough values was modeled. Results: Of 34 subjects on PK-guided prophylaxis with rAHF-PFM targeting 1% trough every third day, 19 (56%) had no spontaneous BE during one year observation at FVIII levels (median) above the theoretical trough value of 1%. The number (%) of subjects with no spontaneous/non-trauma BE at FVIII levels (median) above the theoretical trough value of 3%, 5%, 10%, 15% and 20% levels increased to 71%, 79%, 31 91%, 97%, and 100%, respectively (Figure 1). All 57 spontaneous/non-trauma BE occurred at predicted FVIII levels ≤30%. Figure 1 Figure 1. Conclusions: Evaluation of individual bleeding events and treatment records for this prophylaxis study population, most of which had pre-established hemophilic arthropathy, suggests that some patients may require higher trough targets to achieve an ideal outcome. Targeting a 1% trough FVIII level every 72 hrs was effective with 56% of subjects achieving a full year with no spontaneous BE. Modeling showed that targeting a 3 - 5% FVIII trough level would have led to more than 75% overall achieving zero spontaneous annual bleed rate (ABR), and that others may have benefitted from trough targets even as high as ≥15%. While this study could not necessarily account for or examine the role of differing levels of physical activity and/or arthropathy on levels of bleeding risk, modeling of FVIII levels post-infusion using individual PK parameters and infusion records along with the contemporaneous overlay of BE should provide valuable insight when designing the optimal, personalized prophylaxis regimen for patients. Valentino LA, Mamonov V, Hellmann A, et al. J Thromb Haemost 2012 Mar; 10(3): 359-67. Disclosures Spotts: Baxter Healthcare Corporation: Employment, Equity Ownership. Pipe:Baxter: Consultancy, Honoraria. Berntorp:Baxter: Honoraria. Collins:Baxter: Consultancy, Honoraria. Oh:Baxter: Employment. Valentino:Baxter: Consultancy, Employment, Honoraria, Research Funding; Bayer: Consultancy, Honoraria, Research Funding; Biogen: Consultancy, Honoraria, Research Funding; CSL Behring: Consultancy, Honoraria, Research Funding; GTC Biotherapeutics: Consultancy, Honoraria, Research Funding; rEVO Biologics: Consultancy, Honoraria; Inspiration Bioscience: Consultancy, Honoraria, Research Funding; NovoNordisk: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding." @default.
• W2979527793 created "2019-10-18" @default.
• W2979527793 creator A5002749259 @default.
• W2979527793 creator A5020488137 @default.
• W2979527793 creator A5063823763 @default.
• W2979527793 creator A5064943069 @default.
• W2979527793 creator A5065311756 @default.
• W2979527793 creator A5083938702 @default.
• W2979527793 creator A5085529896 @default.
• W2979527793 creator A5086748531 @default.
• W2979527793 date "2014-12-06" @default.
• W2979527793 modified "2023-10-16" @default.
• W2979527793 title "Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis" @default.
• W2979527793 doi "https://doi.org/10.1182/blood.v124.21.689.689" @default.
• W2979527793 hasPublicationYear "2014" @default.
• W2979527793 type Work @default.
• W2979527793 sameAs 2979527793 @default.
• W2979527793 citedByCount "2" @default.
• W2979527793 countsByYear W29795277932015 @default.
• W2979527793 countsByYear W29795277932020 @default.
• W2979527793 crossrefType "journal-article" @default.
• W2979527793 hasAuthorship W2979527793A5002749259 @default.
• W2979527793 hasAuthorship W2979527793A5020488137 @default.
• W2979527793 hasAuthorship W2979527793A5063823763 @default.
• W2979527793 hasAuthorship W2979527793A5064943069 @default.
• W2979527793 hasAuthorship W2979527793A5065311756 @default.
• W2979527793 hasAuthorship W2979527793A5083938702 @default.
• W2979527793 hasAuthorship W2979527793A5085529896 @default.
• W2979527793 hasAuthorship W2979527793A5086748531 @default.
• W2979527793 hasBestOaLocation W29795277931 @default.
• W2979527793 hasConcept C126322002 @default.
• W2979527793 hasConcept C141071460 @default.
• W2979527793 hasConcept C2776259030 @default.
• W2979527793 hasConcept C2777288759 @default.
• W2979527793 hasConcept C2781413609 @default.
• W2979527793 hasConcept C2909675724 @default.
• W2979527793 hasConcept C2911091166 @default.
• W2979527793 hasConcept C31785415 @default.
• W2979527793 hasConcept C71924100 @default.
• W2979527793 hasConceptScore W2979527793C126322002 @default.
• W2979527793 hasConceptScore W2979527793C141071460 @default.
• W2979527793 hasConceptScore W2979527793C2776259030 @default.
• W2979527793 hasConceptScore W2979527793C2777288759 @default.
• W2979527793 hasConceptScore W2979527793C2781413609 @default.
• W2979527793 hasConceptScore W2979527793C2909675724 @default.
• W2979527793 hasConceptScore W2979527793C2911091166 @default.
• W2979527793 hasConceptScore W2979527793C31785415 @default.
• W2979527793 hasConceptScore W2979527793C71924100 @default.
• W2979527793 hasIssue "21" @default.
• W2979527793 hasLocation W29795277931 @default.
• W2979527793 hasOpenAccess W2979527793 @default.
• W2979527793 hasPrimaryLocation W29795277931 @default.
• W2979527793 hasRelatedWork W2028032203 @default.
• W2979527793 hasRelatedWork W2047967234 @default.
• W2979527793 hasRelatedWork W2118496982 @default.
• W2979527793 hasRelatedWork W2360716590 @default.
• W2979527793 hasRelatedWork W2439875401 @default.
• W2979527793 hasRelatedWork W2678470159 @default.
• W2979527793 hasRelatedWork W2762267996 @default.
• W2979527793 hasRelatedWork W2979527793 @default.
• W2979527793 hasRelatedWork W4232670518 @default.
• W2979527793 hasRelatedWork W4246416337 @default.
• W2979527793 hasVolume "124" @default.
• W2979527793 isParatext "false" @default.
• W2979527793 isRetracted "false" @default.
• W2979527793 magId "2979527793" @default.
• W2979527793 workType "article" @default.